DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in th...
| DXCM | Peers | Sector | |
|---|---|---|---|
Market Cap | 26.471 B | 144.5 M | 64.31 M |
Price % of 52 Week High | 47.7% | 62.9% | 62.1% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | 2.7% | -1.5% | -0.7% |
1 Year Price Total Return | -51.2% | -29.1% | -12.1% |
Beta (5 Year) | 1.29 | 1.21 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 2,910 | 3,622 | 4,033 | 1,035 | 1,114 |
| Operating Income | 391 | 598 | 600 | 217 | 189 |
| Net Profit | 341 | 542 | 576 | 256 | 152 |
| Diluted EPS | 0.82 | 1.30 | 1.42 | 0.62 | 0.38 |
| EBITDA | 547 | 784 | 818 | 269 | 247 |
| Balance Sheet | |||||
| Cash & ST Invest. | 2,456 | 2,724 | 2,579 | 2,724 | 2,579 |
| Current Assets | 3,669 | 4,426 | 4,301 | 4,426 | 4,301 |
| Total Assets | 5,392 | 6,265 | 6,485 | 6,265 | 6,485 |
| Current Liabilities | 1,839 | 1,556 | 2,932 | 1,556 | 2,932 |
| Total Liabilities | 3,260 | 4,196 | 4,382 | 4,196 | 4,382 |
| Total Equity | 2,132 | 2,069 | 2,103 | 2,069 | 2,103 |
| Total Debt | 2,145 | 2,594 | 2,594 | 2,594 | 2,594 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 670 | 749 | 990 | 134 | 301 |
| Cash From Investing | (522) | (507) | (208) | 415 | (304) |
| Cash From Financing | (553) | (319) | (735) | (632) | (1.60) |
| Free Cash Flow | 305 | 512 | 631 | 81 | 177 |